Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) Return on Invested Capital (2020 - 2025)

Gain Therapeutics has reported Return on Invested Capital over the past 6 years, most recently at 3.82% for Q3 2025.

  • Quarterly results put Return on Invested Capital at 3.82% for Q3 2025, down 177.0% from a year ago — trailing twelve months through Sep 2025 was 3.82% (down 177.0% YoY), and the annual figure for FY2024 was 2.07%, down 67.0%.
  • Return on Invested Capital for Q3 2025 was 3.82% at Gain Therapeutics, down from 3.7% in the prior quarter.
  • Over the last five years, Return on Invested Capital for GANX hit a ceiling of 0.2% in Q2 2021 and a floor of 3.82% in Q3 2025.
  • Median Return on Invested Capital over the past 5 years was 1.73% (2023), compared with a mean of 1.64%.
  • Biggest five-year swings in Return on Invested Capital: tumbled -182bps in 2023 and later skyrocketed 42bps in 2024.
  • Gain Therapeutics' Return on Invested Capital stood at 0.38% in 2021, then crashed by -256bps to 1.36% in 2022, then tumbled by -63bps to 2.22% in 2023, then dropped by -14bps to 2.54% in 2024, then plummeted by -51bps to 3.82% in 2025.
  • The last three reported values for Return on Invested Capital were 3.82% (Q3 2025), 3.7% (Q2 2025), and 3.14% (Q1 2025) per Business Quant data.